Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted. The results of the potent small molecule inhibitor, XL784 meet the criteria for submission of the compound to GlaxoSmithKline (GSK) for evaluation under the product development and commercialization agreement between Exelixis and GSK.
George Scangos, president and CEO of Exelixis, said: “We obviously are disappointed that this trial did not meet its primary endpoint. However, the compound was well tolerated, and we are continuing to analyze the data to determine if the compound may have utility in the treatment of diabetic nephropathy. We will provide an update on our plans for XL784 once we complete our analysis of the data.”